Melbourne, Victoria, Australia The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Partners Investment, Ost Investment, Mirae Asset Venture Investment.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2017. Deals in the range of 1 - 5 millions dollars are the general things for fund.
Among the most popular portfolio startups of the fund, we may highlight Bionetix. We can highlight the next thriving fund investment areas, such as Biotechnology, Agriculture.
Related Funds
| Fund Name | Location |
| 3 Wise Ventures | Delaware, United States, Wilmington |
| Amolino | - |
| BD Ventures | Bangladesh, Dhaka, Dhaka Division |
| BI.Garage | Japan, Tokyo |
| Blazar Ventures LLC | Alexandria, United States, Virginia |
| Broad Beach Ventures | California, Los Angeles, United States |
| Castlight Health | California, San Francisco, United States |
| CK Venture Capital | Bayern, Germany, Unterschleißheim |
| FURUKAWA ELECTRIC Japan | Chiyoda, Japan |
| Jindong Capital Investment | Chengguan District, China, Lhasa |
| K3 Ventures | Central Region, Singapore, Singapore |
| Morgan Stanley Private Equity Asia | - |
| Promus Capital | Chicago, Illinois, United States |
| Raven Ventures Australia | Australia, New South Wales, Sydney |
| Service Provider Capital | Colorado, Golden, United States |
| ShengJing360 | Beijing, Beijing, China |
| Xin Chang Electronics Technology | - |
| YouWeCan | China, Shanghai, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Catch Table | $26M | 13 Apr 2022 | Seongnam, Kyonggi-do, South Korea | ||
KaliVir Immunotherapeutics | 16 Mar 2022 | Pittsburgh, Pennsylvania, United States | |||
| $1M | 16 Sep 2020 | Wilmington, Delaware, United States | |||
Bionetix Therapeutics | $3M | 22 Dec 2017 | South Korea, Gyeonggi-do, South Korea | ||
Bionetix Therapeutics | 01 Mar 2017 | South Korea, Gyeonggi-do, South Korea |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Catch Table | $26M | 13 Apr 2022 | Seongnam, Kyonggi-do, South Korea | ||
KaliVir Immunotherapeutics | 16 Mar 2022 | Pittsburgh, Pennsylvania, United States | |||
| $1M | 16 Sep 2020 | Wilmington, Delaware, United States | |||
Bionetix Therapeutics | $3M | 22 Dec 2017 | South Korea, Gyeonggi-do, South Korea | ||
Bionetix Therapeutics | 01 Mar 2017 | South Korea, Gyeonggi-do, South Korea |
